Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...

Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, ...

Duvakitug, a drug candidate with a "best in class efficacy profile," has shown strong remission rates in treatment-refractory patients. Analysts are particularly optimistic about its consistent ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV’574/SAR447189) for moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of ...

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across ...

The company's pipeline is equally promising, with several potential blockbusters in development. Duvakitug, a drug candidate with a "best in class efficacy profile," has shown strong remission rates ...